Media Thread, page-17478

Good morning all

It looks like the City of Hope team just did a conference presentation on the Check-acc trial (CF33 in Triple Neg Breast Cancer).

The Abstract is here:

https://aacrjournals.org/cancerimmunolres/article/13/2_Supplement/A105/751449

Results - as expected. Only 9 subjects, and because it was at the very start of testing of CF33 they were bound b y the FDA's extremely cautious dosage limitation.. The highest they went was 10⁶ - which is a tiny dose. Even so - most patients showed the expected immune response.

The conclusions:

CF33-hNIS-anti-PD-L1 induces tumor inflammation and immune activation as marked by increased tumor infiltration of CD4+ and CD8+ T cells, increased PD-L1 expression, and increased PD-1-positive T cells. Combination trials with CF33-hNIS and immune checkpoint inhibitor for the treatment of advanced solid tumors are ongoing. Additionally, more studies are needed to evaluate the use of OV in patients with high-risk stage II-III breast cancers.

Interesting, but we still need to wait for further data from the MAST trial.

Cheers

Dave